logo

CSTL

Castle Biosciences·NASDAQ
--
--(--)
--
--(--)

CSTL fundamentals

Castle Biosciences (CSTL) expects to report earnings on Feb 26, 2026, with estimated revenue of 79.90M (YoY -6.90%), and EPS at -0.2588 (YoY -180.88%).
Revenue estimate / YoY
79.90M
-6.90%
EPS estimate / YoY
-0.2588
-180.88%
Report date
Feb 26, 2026
Earnings Call
4:30 PM on Feb 26, 2026
Meeting link.
EPS
Revenue

Revenue & Expenses

CSTL has released its 2025 Q3 earnings report, with revenue of 83.04M, reflecting a YoY change of -3.19%, and net profit of -501.00K, showing a YoY change of -122.08%. The Sankey diagram below clearly presents CSTL's revenue sources and cost distribution.

Key Indicators

Castle Biosciences (CSTL) key financial stats and ratios, covering profitability, financial health, and leverage.
Castle Biosciences (CSTL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Castle Biosciences (CSTL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Castle Biosciences (CSTL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Castle Biosciences (CSTL) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Castle Biosciences (CSTL) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield